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Abstract
Herein we present the unique case of a 21-year-old African American woman who presented
with psychotic features and the incidental finding of basal ganglia calcifications on computed
tomography (CT) scan of the head. She was initially presumed to have Fahr’s syndrome in the
context of idiopathic bilateral basal ganglia calcifications and psychotic features. Genetic
testing performed revealed the deletion of 22q11.2, thus establishing the diagnosis of DiGeorge
syndrome. This case highlights the importance of noticing subtle physical exam findings along
with laboratory findings as this led to the diagnosis of DiGeorge syndrome for this patient. This
case is unique in two aspects; first, the finding of basal ganglia calcification via CT of the brain
in patients with DiGeorge syndrome has rarely been reported in the literature. Second, this case
highlights the strong genetic predisposition for schizophrenia in patients with DiGeorge
syndrome.
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This case report serves to illustrate the occurrence of psychotic disturbances in patients with
DiGeorge syndrome. In accordance with the recent data, 25% to 33% of individuals with
DiGeorge syndrome develop psychiatric features [1]. In comparison to other cases that have
been published, this DiGeorge syndrome case is unique as the first break psychosis was the
initial presentation of the 22q11.2 deletion. This highlights the variable clinical presentation of
DiGeorge syndrome in each patient and the need for a multidisciplinary methodology to
diagnose and treat it.
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Case Presentation
The patient is a 21-year-old African American woman, unemployed, living in Brooklyn, New
York, with no prior psychiatric history. She was brought in by emergency medical services at the
request of her mother due to the patient’s increased aggression and paranoia at home. As per
her mother’s account, the patient began acting bizarre two months ago when she left her home
to stay with her boyfriend. The mother was contacted by the patient a few days later concerning
paranoid ideation that people were trying to kill her. The patient also tried to attack her mother
while she was driving a car. Additionally, she also started accusing her family members of being
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replacements (Capgras syndrome). As per her mother’s account, the patient had been intrusive
towards strangers on the street, reading the Bible and getting in people’s faces.
When the patient was presented to the hospital, she seemed very confused, internally
preoccupied, disorganized, and providing delayed and inappropriate responses to questions
when asked. This was her first psychiatric presentation. It was noted that she had an elongated
face with small ears rotated backward and exhibited hypernasal speech. She appeared to be
labile, crying for no apparent reason then later singing out loud. The patient refused to come
out of her room for an initial interview. During her interview, she remained evasive and
guarded. Her thought process was illogical, and her thought content was delusional (e.g., she
thought her mother was the devil). She denied visual, tactile, olfactory, and gustatory
hallucinations but endorsed hearing Jesus’s voice telling her that everything was going to be
ok. She denied any suicidal or homicidal ideation. The patient admitted using illicit drugs in the
past including marijuana, Ecstasy, Molly, and alcohol but could not quantify them. Urine
toxicology testing was performed along with urinary cannabinoid and 3,4methylenedioxymethamphetamine (Ecstasy) testing; all test results were negative. Assays for
thyroid-stimulating hormone, the venereal disease research laboratory test for syphilis,
antinuclear antibody, and an enzyme-linked immunosorbent assay for the human
immunodeficiency virus were also ordered as a part of her workup; all results were within
normal limits. A complete metabolic panel was ordered, and her serum calcium was found to be
low (4.14 mg/dL). An electrocardiogram and echocardiogram were performed, but their findings
were normal. After an endocrinology consultation, the patient was started on intravenous
calcium carbonate. She was medicated with olanzapine and aripiprazole. She was initially
started on 2 mg olanzapine then gradually titrated up to 20 mg of olanzapine and 10 mg of
aripiprazole, but these displayed marked extrapyramidal side effects, specifically increased
rigidity and dystonia of the neck and jaw muscles, so these were abruptly discontinued. Given
her poor response to multiple antipsychotics, exaggerated extrapyramidal symptoms (EPS),
reaction to olanzapine, and suboptimal absolute neutrophil count, she was started on low-dose
quetiapine at 25 mg and gradually titrated up to 400 mg twice a day (BID) in the hospital to
target her psychosis, lorazepam to address her agitation, and benztropine for her EPS. We also
considered using a newer agent, pimavanserin to target her psychosis given the rapid
development of Parkinsonian features after the use of olanzapine, but this could not be
initiated due to the patient’s insurance’s reluctance to cover it. The patient showed
improvement of her psychosis on quetiapine 400 mg BID, becoming more logical and goaloriented.
A computed tomography (CT) scan without contrast of the head was ordered as a workup of her
first-time psychosis. The CT showed extensive bilateral asymmetrical calcifications involving
the bilateral basal ganglia including the globus pallidus, putamen, caudate, thalamus, dentate,
and subcortical white matter.
The patient had a history of motor vehicle injury (MVI) three years ago as a pedestrian. From
the MVI, she suffered facial trauma, splenic laceration, and an L3-L4 transverse process
fracture. At that time, the patient recovered completely with no sequelae. However, a CT of her
head performed at that time showed incidental bilateral basal ganglia calcifications. It was
recommended that the patient take oral calcium and continue follow-up evaluations; she never
did. Of note, the current CT was unchanged from the previous CT of her head performed three
years ago.
The case was reviewed with the Neuropsychiatry department. They presumptively diagnosed
the patient with Fahr’s syndrome based on the idiopathic basal ganglia calcification and the
patient’s hypoparathyroidism, hypocalcemia, and hyperphosphatemia found via the blood
work. At that point, there was also a slight concern for DiGeorge syndrome as there is evidence
supporting a strong correlation between psychosis and DiGeorge syndrome. This warranted
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genetic testing for 22q chromosomal abnormalities once the patient was psychiatrically stable.
Genetic testing by fluorescence in situ hybridization (FISH) was performed, confirming the
diagnosis of a 22q11.2 deletion.
From the mother’s report, it was also evident as part of the review of the patient’s
developmental history that the patient was born via normal vaginal delivery at term. The only
obvious finding at birth was her long fingers. The pediatrician was consulted, but no other
abnormality was found until the patient was two years old; at that time, she was diagnosed with
a hearing impairment and delayed speech prompting the use of a hearing aid. Afterward, she
received an ordinary education and graduated from high school.
The patient was discharged on a quetiapine 400 mg BID medication regimen. The patient is still
a part of a partial hospitalization program at our hospital and is showing a marked
advancement in her quality of life in terms of her behavior.

Discussion
DiGeorge syndrome or velocardiofacial syndrome, also known in broader terms as chromosome
22q11.2 deletion, is an autosomal dominant neurogenetic condition that has been the focus of
research for many years. It affects between one in 2,000 to 4,000 live births and is mostly due to
a hemizygous three-megabase deletion detectable by FISH on the long arm of chromosome 22.
The deletion includes the TBX1 gene between low-copy repeats LCR22-1 and LCR22-3 [2,3].
DiGeorge syndrome presents with a variable expression of phenotypes ranging from mild to
severe, life-threatening forms depending on what parts of the body are involved and to the
extent they are affected. Some symptoms may be present at birth while others may not be
apparent until later childhood, making it imperative to screen every newborn at birth and every
wellness visit if they show any associated medical or behavioral condition [4]. Associated
medical conditions can include dysmorphic facial features, hypocalcemia, hypoparathyroidism
(due to defective development of pharyngeal pouches), frequent infections, cardiac defects,
hypernasal speech, cleft palate, autoimmune conditions, neurocognitive decline, intellectual
disability, learning disorders, and various other behavioral and mental health issues.
A study published on 1,402 participants from age six to 68 years with 22q11.2 deletion showed
various psychiatric disorders developed from childhood to adulthood, validating the fact that a
22q11.2 deletion is one of the strongest factors for developing psychosis [2]. Attentiondeficit/hyperactivity disorder was most frequent in children with this deletion, and psychosis
was more evident in 41% of adults over age 25 with this deletion [2]. Our case is unique as the
patient presented with psychosis in adolescence. This highlights the fact that schizophrenia
spectrum disorder is a clinical characteristic even in the pediatric and adolescence age group
for individuals with a 22q11.2 deletion. A significant correlation between schizophrenia and a
22q11.2 deletion could be predicted if patients with schizophrenia have an elevated occurrence
of 22q11.2 deletions or if more cases of schizophrenia are detected in patients with 22q11.2
deletion syndrome [3].
Research has shown the importance of catechol-O-methyltransferase (COMT) in developing
psychosis in patients with DiGeorge syndrome. The COMT gene is one of the 24 genes within
the deleted region and has a significant role in neurodevelopment. The haploinsufficiency of
COMT leads to elevated levels of prefrontal dopamine in patients with 22q11.2 deletion,
interfering with their cognitive abilities and contributing to their psychosis [5]. There is also
research evidence supporting the theory that low levels of proline dehydrogenase and COMT in
DiGeorge syndrome are responsible for the phenotypic expression of psychosis spectrum as
there is a defect in the metabolism regulated by these enzymes leading to increased exposure to
catecholamines and proline, increasing the individual’s vulnerability to psychotic expression
[6,7].
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It appears that there are risk factors that increase the susceptibility to psychosis in patients
with DiGeorge syndrome. The 22q11.2 deletion is the most common genetic risk factor for the
development of schizophrenia. Data indicate that when it manifests in children with a 22q11.2
deletion, they experience more severe psychiatric symptoms than other children with
idiopathic developmental disabilities [8]. Psychotic features can present from age 11 until age
26 [9]. The mean age of onset of psychosis in DiGeorge syndrome is still debated as different
studies have shown variation in the age of onset; this could be due to different ages of the
samples being studied and the gradual evolution of psychosis in different patients. However,
our patient displayed some discrepancy with the typical age of onset as she presented to the
hospital in her adolescence with new-onset psychosis and with no prior psychiatric history. Her
physical appearance and psychosis warranted further investigations leading to a genomic
diagnosis of DiGeorge syndrome. Also, some data suggest a difference in the symptomatology
of schizophrenia in patients with DiGeorge syndrome as compared to those without DiGeorge
syndrome. Patients with DiGeorge syndrome exhibit neurobehavioral symptoms in addition to
schizophrenia [9]. This was also obvious in our patient. Brain imaging showed bilateral basal
ganglia calcifications, making us initially contemplate a rare condition called Fahr’s syndrome
as a possible diagnosis in the context of psychosis. However, though it may appear in childhood
or adolescence, the age of onset for Fahr’s syndrome is typically in the 40s or 50s. Genetic
testing at that time excluded Fahr’s syndrome, an inherited neurological disorder characterized
by abnormal calcium deposition in parts of the brain that control body movements. Symptoms
may range from deteriorated motor function to dementia, seizures, and Parkinson’s-like disease
[10]. After genetic confirmation of DiGeorge syndrome, it appeared the most likely reason for
psychiatric disturbances in our patient was due to the 22q11.2 deletion concomitantly
associated with the basal ganglia calcification observed. Patients suffering from DiGeorge
syndrome rarely develop basal ganglia calcification, but in her case, those calcifications were
seen on the CT of her head correlating with her current presentation. These basal ganglia
calcifications can impart an increased risk of Parkinson’s disease in the future, apart from her
current psychosis and can be sensitive to the development of EPS after the use of
antipsychotics.

Conclusions
In light of the above case report and discussion, DiGeorge syndrome serves as a hereditary
model for the development of schizophrenia. It is therefore imperative that psychiatrists should
evaluate every young individual with a 22q11.2 deletion for symptoms of psychosis. Given the
fact that schizophrenia and a 22q11.2 deletion are strongly correlated, it is also recommended
to obtain genetic testing in patients with recent onset psychosis if they show features of
DiGeorge syndrome. More research should also be conducted to explore the role of alternative
agents like pimavanserin that have a strong predilection for serotonin receptors rather than
dopamine receptors in treating psychosis in patients with a 22q11.2 deletion. Also, more cases
should support the incidence of basal ganglia calcification in patients with a 22q11.2 deletion
(DiGeorge syndrome) as this is a rare finding evident in our patient.
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